醣聯 (4168)

About 醣聯

GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company's development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under preclinical stage; GNX203, glycan-directed antibody drug currently under the lead optimization stage; and GNX1021, a first-in-class antibody–drug conjugate currently under preclinical stage. It is also involved in the development of SPD (Denosumab), a humanized IgG2 antibody that is in phase 3 clinical trial for the treatment of osteoporosis and cancer bone metastases. The company was incorporated in 2001 and is based in New Taipei City, Taiwan.

Headquarters: New Taipei City, TW · Website: https://www.glyconex.com.tw

Frequently asked questions about 醣聯 (4168)

What is 醣聯 (4168)?

醣聯 (4168) is a publicly traded company in the Healthcare sector (生技醫療業), listed on TPEx. Macroplane maps its supply-chain relationships, suppliers, buyers, financial health, and competitive positioning.